Chris Kim, Liminatus Pharma CEO
A fledgling biotech goes SPAC route to bankroll cancer vaccine, CAR-T and CD47
A relatively unknown clinical-stage biotech — backed by a Korean lighting company and focused on a cancer vaccine out of a Thomas Jefferson University lab …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.